home / stock / tryp:cc / tryp:cc quote
Last: | $0.08 |
---|---|
Change Percent: | 0.0% |
Open: | $0.08 |
Close: | $0.08 |
High: | $0.08 |
Low: | $0.08 |
Volume: | 1,270 |
Last Trade Date Time: | 05/05/2022 09:42:44 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$0.08 | $0.08 | $0.08 | $0.08 | $0.08 | 1,270 | 05-05-2022 |
$0.08 | $0.08 | $0.08 | $0.08 | $0.08 | 20,381 | 04-29-2022 |
$0.08 | $0.065 | $0.08 | $0.105 | $0.06 | 812,530 | 04-28-2022 |
$0.07 | $0.07 | $0.07 | $0.075 | $0.06 | 236,754 | 04-27-2022 |
$0.07 | $0.075 | $0.07 | $0.085 | $0.07 | 8,700 | 04-25-2022 |
$0.085 | $0.09 | $0.085 | $0.09 | $0.075 | 89,697 | 04-22-2022 |
$0.085 | $0.08 | $0.085 | $0.09 | $0.08 | 133,420 | 04-20-2022 |
$0.08 | $0.09 | $0.08 | $0.095 | $0.08 | 344,429 | 04-19-2022 |
$0.09 | $0.1 | $0.09 | $0.1 | $0.09 | 79,414 | 04-18-2022 |
$0.095 | $0.09 | $0.095 | $0.095 | $0.08 | 160,487 | 04-12-2022 |
$0.1 | $0.095 | $0.1 | $0.1 | $0.09 | 80,861 | 04-08-2022 |
$0.095 | $0.1 | $0.095 | $0.1 | $0.085 | 127,020 | 04-07-2022 |
$0.095 | $0.095 | $0.095 | $0.095 | $0.095 | 1,010 | 04-06-2022 |
$0.105 | $0.105 | $0.105 | $0.105 | $0.105 | 24,000 | 04-04-2022 |
$0.12 | $0.11 | $0.12 | $0.12 | $0.11 | 15,000 | 03-31-2022 |
$0.12 | $0.115 | $0.12 | $0.125 | $0.105 | 376,401 | 03-29-2022 |
$0.13 | $0.145 | $0.13 | $0.16 | $0.13 | 72,301 | 03-21-2022 |
$0.13 | $0.12 | $0.13 | $0.14 | $0.115 | 49,814 | 03-17-2022 |
$0.115 | $0.14 | $0.115 | $0.14 | $0.115 | 56,263 | 03-16-2022 |
$0.13 | $0.135 | $0.13 | $0.135 | $0.13 | 77,950 | 03-15-2022 |
News, Short Squeeze, Breakout and More Instantly...
Tryp Therapeutics Inc. Company Name:
TRYP:CC Stock Symbol:
CNQC Market:
KELOWNA, BC / ACCESSWIRE / May 1, 2024 / Tryp Therapeutics, Inc. (" Tryp " or the " Company ") ( CSE:TRYP, OTCQB: TRYPF ) and Exopharm Limited ACN 163 765 991 (" Exopharm ") are pleased to announce that completion of the previously announced plan of arrangement (the " Arrangement ") effective ...
Toronto, Ontario--(Newsfile Corp. - Le 24 avril/April 2024) - Tryp Therapeutics Inc. (the "Issuer") has announced that further to the press release dated February 8, 2024, the shareholders of Exopharm Limited ACN 163 765 991 have approved the previously announced plan of arrangement (the “...
Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) , a clinical-stage biotechnology company focused on developing intravenous-infused psilocin (the active metabolite of psilocybin) for diseases with high unmet medical needs, today announced that shareholders of Exopharm Limited ACN 163 765 991 approved...